EuroBiotech: More Articles of Note

Newspapers

> MorphoSys received FDA breakthrough designation for MOR208 in diffuse large B-cell lymphoma. The FDA awarded the regulatory status to the anti-CD19 antibody on the strength of preliminary data from a phase 2 Revlimid combination trial. Release

> Nicox struck a deal with Re-Vana Therapeutics. The partners will look into combining Nicox’s stand-alone nitric oxide-donors with Re-Vana's biodegradable drug delivery platform. Statement

> UniQure moved to capitalize on the positive response to its pipeline switch up with a stock offering. The gene therapy specialist is offering 5 million shares, positioning it to pull in close to $100 million at its recently-risen stock price. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Ergomed reported top-line data from a phase 2 trial of its coagulant PeproStat. The drug cut time to hemostasis by 1.55 minutes compared to standard of care, a statistically-significant difference that resulted in the trial hitting its primary endpoint. Statement

> Mologen received a $10 million investment from Global Corporate Finance. The money equips Mologen to push ahead with its lefitolimod-focused strategy. Lefitolimod is a clinical-phase TLR9 agonist. Release 

> Transgene reported data from a phase 1/1b trial of its hepatitis B immunotherapy TG1050. Two-fifths of participants experienced drug-related adverse events but none were more severe than grade 2. Most of the adverse events were injection site reactions. Statement

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.